Invention Grant
- Patent Title: 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors
-
Application No.: US15259505Application Date: 2016-09-08
-
Publication No.: US09724347B2Publication Date: 2017-08-08
- Inventor: Kazuhiro Ito , Catherine Elisabeth Charron , John King-Underwood , Stuart Thomas Onions , Alistair Ian Longshaw
- Applicant: Respivert Ltd.
- Applicant Address: unknown Buckinghamshire
- Assignee: Respivert, Ltd.
- Current Assignee: Respivert, Ltd.
- Current Assignee Address: unknown Buckinghamshire
- Agent Ada O. Wong
- Priority: EP11183688 20111003
- Main IPC: C07D403/12
- IPC: C07D403/12 ; A61K31/506 ; A61K45/06 ; A61K31/215 ; A61K31/351 ; A61K9/00
Abstract:
There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
Public/Granted literature
- US20170007604A1 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4 -YL) OXY) NAPTHTHALEN-1 - YL) UREAS AS P38 MAP KNASE INHIBITORS Public/Granted day:2017-01-12
Information query
